Carl Adams
Comptroller/Controller/Auditor bei TELEDYNE TECHNOLOGIES INCORPORATED
Profil
Carl Adams is currently the Chief Audit Executive & Vice President at Teledyne Technologies, Inc. He previously worked as the Chief Financial Officer & Vice President at NeuroSigma, Inc. in 2014.
He completed his undergraduate degree at California State University-Northridge.
Aktive Positionen von Carl Adams
Unternehmen | Position | Beginn |
---|---|---|
TELEDYNE TECHNOLOGIES INCORPORATED | Comptroller/Controller/Auditor | 01.12.2023 |
Ehemalige bekannte Positionen von Carl Adams
Unternehmen | Position | Ende |
---|---|---|
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | Finanzdirektor/CFO | - |
Ausbildung von Carl Adams
California State University-Northridge | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
TELEDYNE TECHNOLOGIES INCORPORATED | Electronic Technology |
Private Unternehmen | 1 |
---|---|
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | Health Technology |